FDA approves first gene-editing treatments for human illness
The FDA has approved the first gene-editing treatments for sickle cell disease, marking a milestone in the field of gene-editing.
The treatments have the potential to provide more targeted and effective treatments for rare diseases with limited current options.
F.D.A. Approves Sickle Cell Treatments, Including One That Uses CRISPR
The Food and Drug Administration has approved the first gene editing therapy and conventional gene therapy for sickle cell disease.
Obstacles to treatment include limited access to authorized medical centers, individualized procedures, and high costs.
The CRISPR Era Is Here
Gene-editing technology CRISPR has successfully treated a patient with sickle-cell disease, providing hope for future treatments.
The treatment resulted in the patient living virtually symptom-free, with 29 out of 30 eligible patients experiencing zero pain crises after treatment.
The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to follow
U.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.
The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.
The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level.
UK authorizes first gene therapy for treating sickle cell disease
The UK's MHRA has approved the use of a gene-editing therapy for patients with sickle cell disease and beta thalassemia.
The therapy, called Casgevy, is the first-ever approved therapy that uses CRISPR-based gene editing technology.
The therapy has shown high efficacy in relieving severe pain associated with these blood disorders and could potentially replace the current standard of care.
The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to follow
U.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.
The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.
The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level.
UK authorizes first gene therapy for treating sickle cell disease
The UK's MHRA has approved the use of a gene-editing therapy for patients with sickle cell disease and beta thalassemia.
The therapy, called Casgevy, is the first-ever approved therapy that uses CRISPR-based gene editing technology.
The therapy has shown high efficacy in relieving severe pain associated with these blood disorders and could potentially replace the current standard of care.
U.K. Is First to Approve a CRISPR-Based Therapy, Covering Two Blood Disorders
The UK has authorized a gene-editing medicine for treating sickle cell disease and beta thalassemia, marking the first approval worldwide for a therapy based on CRISPR technology.
The therapy, known as Casgevy, involves editing a gene in a patient's stem cells to produce high levels of fetal hemoglobin.
Casgevy offers a potentially curative treatment option for these inherited blood disorders, reducing the need for chronic therapies and blood transfusions.
Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approval
Regulators in Britain have approved the first treatment derived from CRISPR, called Casgevy, for sickle-cell disease and beta thalassemia.
About 2,000 patients in Britain are expected to be eligible for Casgevy treatment.
The FDA is expected to approve Casgevy for sickle-cell patients in the US in early December.
Crispr gene editing shown to permanently lower high cholesterol
Researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol in a small test on people.
The gene-editing treatment aims to permanently lower cholesterol by using Crispr to edit a gene in the liver.
Preliminary results of the experiment were presented at the American Heart Association's annual meeting.
A Single Infusion of a Gene-Editing Treatment Lowered High Cholesterol
Researchers have shown that a single infusion of a gene-editing treatment can reduce cholesterol levels in people.
The treatment aims to permanently lower cholesterol by using Crispr to edit a gene in the liver, and initial results show significant reductions in LDL cholesterol.
Gene editing could provide a lasting option for treating hereditary high cholesterol, replacing the need for long-term medication.
Goodbye Statins? New Gene Editing Therapy Slashes High Cholesterol
A novel gene editing therapy using base editing lowered "bad" cholesterol levels in individuals with FH by as much as 55 percent.
The therapy could potentially provide a single-course treatment option for deep LDL lowering for decades without the need for daily pills or intermittent injections.
New Gene Editing Treatment Cuts Dangerous Cholesterol in Small Study
Gene editing treatment shows promise in lowering cholesterol levels in patients with severe heart disease
Treatment has the potential to transform preventive cardiology
Crispr gene editing shown to permanently lower high cholesterol
Researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol in a small test on people.
The gene-editing treatment aims to permanently lower cholesterol by using Crispr to edit a gene in the liver.
Preliminary results of the experiment were presented at the American Heart Association's annual meeting.
A Single Infusion of a Gene-Editing Treatment Lowered High Cholesterol
Researchers have shown that a single infusion of a gene-editing treatment can reduce cholesterol levels in people.
The treatment aims to permanently lower cholesterol by using Crispr to edit a gene in the liver, and initial results show significant reductions in LDL cholesterol.
Gene editing could provide a lasting option for treating hereditary high cholesterol, replacing the need for long-term medication.
Goodbye Statins? New Gene Editing Therapy Slashes High Cholesterol
A novel gene editing therapy using base editing lowered "bad" cholesterol levels in individuals with FH by as much as 55 percent.
The therapy could potentially provide a single-course treatment option for deep LDL lowering for decades without the need for daily pills or intermittent injections.
New Gene Editing Treatment Cuts Dangerous Cholesterol in Small Study
Gene editing treatment shows promise in lowering cholesterol levels in patients with severe heart disease
Treatment has the potential to transform preventive cardiology